DalsnaFinance Account

Nuvation Bio Inc Class a $NUVB

Health Care

Russell 2000 New York

Create a scorecard

$4.70

-0.15 (-3.09%)

As of Oct 22, 2026, 9:30 PM EDT · cached

Price history

Loading chart…

Nuvation Bio Inc Class a (NUVB) is trading down at $4.70 (-3.09%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Nuvation Bio Inc Class a revenue & net income history (FY2020–FY2025)

RevenueNet incomeNet margin (right axis, %)

Nuvation Bio Inc Class a annual financial statements
	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	—	—	—	$0	$7.87M	$62.9M
Growth (year over year)	—	—	—	—	—	+699.0%
Gross profit	—	—	—	$0	$795.0K	—
Gross margin	—	—	—	—	10.1%	—
Operating income	−$43.6M	−$93.3M	−$119.7M	−$99.8M	−$592.6M	−$213.1M
Operating margin	—	—	—	—	−7527.3%	−338.7%
Net income	−$41.7M	−$86.8M	−$104.2M	−$75.8M	−$567.9M	−$204.6M
Net margin	—	—	—	—	−7213.8%	−325.3%
EPS (diluted)	−$0.43	−$0.44	−$0.48	−$0.35	−$2.11	−$0.60
Balance sheet
Cash and equivalents	$29.8M	$132.4M	$101.1M	$42.6M	$35.7M	$164.1M
Total assets	$221.8M	$776.2M	$672.1M	$621.5M	$540.6M	$594.8M
Total liabilities	$6.71M	$30.2M	$17.1M	$16.4M	$76.8M	$289.1M
Long-term debt	—	—	—	—	—	$47.2M
Shareholders' equity	$215.1M	$746.0M	$655.1M	$605.1M	$463.8M	$305.7M
Cash flow
Operating cash flow	−$36.5M	−$68.2M	−$96.1M	−$68.0M	−$130.4M	−$173.4M
Capital expenditure	—	—	—	—	$0	$8.00M
Free cash flow	—	—	—	—	−$130.4M	−$181.4M

RevenueNet incomeNet margin (right axis, %)

Nuvation Bio Inc Class a quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$727.0K	—	$3.08M	$4.83M	$13.1M	—	$83.2M	$31.7M
Growth (year over year)	—	—	—	+236.8%	+1704.7%	—	+2598.7%	+555.6%
Gross profit	−$788.0K	—	$990.0K	$2.26M	$9.77M	—	—	—
Gross margin	−108.4%	—	32.1%	46.7%	74.5%	—	—	—
Operating income	−$48.1M	—	−$59.0M	−$63.6M	−$56.4M	—	$3.88M	−$51.0M
Operating margin	−6616.4%	—	−1913.2%	−1315.7%	−430.1%	—	4.7%	−161.1%
Net income	−$41.2M	—	−$53.2M	−$59.0M	−$55.8M	—	$5.40M	−$62.8M
Net margin	−5668.5%	—	−1726.2%	−1220.9%	−425.2%	—	6.5%	−198.3%
EPS (diluted)	−$0.15	—	−$0.16	−$0.17	−$0.16	—	$0.01	−$0.18
Balance sheet
Cash and equivalents	$30.0M	$35.7M	$48.0M	$248.0M	$98.9M	$164.1M	$125.4M	$258.6M
Total assets	$571.6M	$540.6M	$492.5M	$647.2M	$601.6M	$594.8M	$610.2M	$744.5M
Total liabilities	$68.9M	$76.8M	$73.0M	$274.3M	$275.7M	$289.1M	$290.7M	$490.6M
Long-term debt	—	—	—	$47.0M	$47.1M	$47.2M	$47.3M	$242.6M
Shareholders' equity	$502.7M	$463.8M	$419.5M	$372.9M	$325.9M	$305.7M	$319.6M	$253.9M
Cash flow
Operating cash flow	−$31.1M	—	−$42.6M	−$48.2M	−$52.9M	—	$5.07M	−$43.0M

From Nuvation Bio Inc Class a's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Filings on SEC EDGAR →